STOCK TITAN

Augmedix Inc - AUGX STOCK NEWS

Welcome to our dedicated news page for Augmedix (Ticker: AUGX), a resource for investors and traders seeking the latest updates and insights on Augmedix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Augmedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Augmedix's position in the market.

Rhea-AI Summary
Augmedix, Inc. (Nasdaq: AUGX) has announced the commencement of an underwritten public offering of 5,500,000 shares of its common stock, with an option for underwriters to purchase an additional 15% of the shares. The company intends to use the net proceeds for increased investment in sales and marketing, research and development, general and administrative costs, working capital, capital expenditures, and general corporate purposes. A material portion of the net proceeds will be allocated toward the acceleration of Augmedix’s product roadmap, including offerings for use in the emergency department care setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.31%
Tags
offering
-
Rhea-AI Summary
Augmedix reported strong financial results for the third quarter of 2023, with revenue of $11.8 million, a 50% increase compared to the same period last year. The company achieved a net revenue retention rate of 157% for Health Enterprise customers. Gross margin increased by 390 basis points to 49.5%. The company's GAAP net loss narrowed to $4.4 million, and EBITDA losses declined to $3.7 million. Augmedix also launched Augmedix Go, a fully automated scalable AI medical documentation solution, and established strategic collaborations with three digital health companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.19%
Tags
none
-
Rhea-AI Summary
Augmedix (Nasdaq: AUGX) will report financial results for Q3 2023 on November 6, 2023, after the market closes. The conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET and can be accessed through the company's website or by phone. The webcast will be available for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
earnings
Rhea-AI Summary
Augmedix announces strategic collaborations with Myndshft, Ellipsis Health, and The Sullivan Group to enhance healthcare enterprise efficiency and patient outcomes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
partnership
-
Rhea-AI Summary
Augmedix announces the early access release of Augmedix Go, a clinician-controlled mobile app that uses generative AI to create automated draft medical notes after each patient visit. The product is highly scalable and priced to appeal to a broad base of healthcare systems. It offers features such as summaries of key medical events and reminders of unfinished notes. Augmedix Go can be integrated into leading electronic health record systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
AI
-
Rhea-AI Summary
Augmedix appoints inaugural AI Advisory Council members
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
AI
Rhea-AI Summary
Augmedix expands medical documentation products to behavioral healthcare field
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
none
-
Rhea-AI Summary
Augmedix earns HITRUST certification for information security, validating commitment to strong cybersecurity and regulations. This achievement places Augmedix in an elite group of organizations worldwide. Augmedix takes compliance and information risk management seriously, ensuring patient information is protected. Customers can trust Augmedix to address industry threats and maintain compliance, data protection, and privacy requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
none
-
Rhea-AI Summary
Augmedix announces participation in investor conferences during September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
conferences
Rhea-AI Summary
Augmedix reports strong Q2 2023 financial results with revenue of $10.8 million, a 47% YoY increase. Dollar-based Net Revenue Retention at 148%. Gross margin increased to 47.0%. EBITDA losses declined to $4.2 million. Cash, cash equivalents, and restricted cash were $25.3 million as of June 30, 2023. Revenue guidance for 2023 is at least $43.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.66%
Tags
none
Augmedix Inc

Nasdaq:AUGX

AUGX Rankings

AUGX Stock Data

196.16M
28.78M
10.86%
78.68%
1.48%
All Other Business Support Services
Administrative and Support and Waste Management and Remediation Services
Link
United States
San Francisco

About AUGX

augmedix is a telemedicine charting service for healthcare providers that eliminates the 17 hours each week providers spend on ehr documentation. using wearable technology to connect their clinic with the augmedix charting service, providers can focus on what they do best: taking care of patients.